Randomized Clinical Trial of Matching Client Alcohol Use Disorder Severity and Level of Cognitive Functioning to Treatment Setting: A Partial Replication and Extension

被引:4
|
作者
Rychtarik, Robert G. [1 ]
McGillicuddy, Neil B. [1 ]
Papandonatos, George D. [2 ]
Whitney, Robert B. [3 ]
Connors, Gerard J. [1 ]
机构
[1] Univ Buffalo State Univ New York, Res Inst Addict, 1021 Main St, Buffalo, NY 14203 USA
[2] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA
[3] Univ Buffalo State Univ New York, Dept Family Med, Buffalo, NY 14203 USA
关键词
alcohol use disorders; treatment settings; inpatient; outpatient; expectancy; OUTPATIENT TREATMENT; INPATIENT; PSYCHOTHERAPY; EXPECTATIONS; MECHANISMS; ABUSE;
D O I
10.1037/adb0000253
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
In a tightly controlled, clinical research environment, Rychtarik et al. (2000) found that individuals with an alcohol use disorder (AUD) benefited more from inpatient (IP) than outpatient care, if they presented with high alcohol problem severity and/or low cognitive functioning. This study sought to (a) validate and extend these findings within the uncontrolled environment of a community-based treatment center and (b) test whether inpatients had fewer days of involuntary abstinence (e.g., incarcerations), controlling for differences in treatment expectancy across care settings. Clients (N = 176) with an AUD were deterministically assigned to inpatient-need group (needs IP = high severity and/or low cognitive functioning; no need for IP = neither high severity nor low cognitive functioning). Within need group, participants were randomly assigned to 21 days of routine inpatient or outpatient care, plus 6 months of continuing care. Primary outcomes of percentage of days abstinent (PDA), monthly point prevalence abstinence (PPA), and drinks per drinking day (DDD), and the secondary outcome of involuntary abstinence were assessed over 18 months. Among high-severity participants, inpatients significantly reduced DDD, and outpatients did not. Neither problem severity nor cognitive functioning moderated other setting effects. Treatment expectancy, assessed after being informed of scheduled setting, was higher among inpatients than outpatients. High-expectancy inpatients maintained the highest PDA throughout follow-up, had the highest PPA for most of follow-up, and delayed peak prevalence of involuntary abstinence by 6 months. In sum, the Alcohol Problem Severity x Setting interaction on DDD appears robust. The potential moderating role of expectancy will warrant further study.
引用
收藏
页码:513 / 523
页数:11
相关论文
共 50 条
  • [41] rTMS Reduces Craving and Alcohol Use in Patients with Alcohol Use Disorder: Results of a Randomized, Sham-Controlled Clinical Trial
    Belgers, Maarten
    Van Eijndhoven, Philip
    Markus, Wiebren
    Schene, Aart H.
    Schellekens, Arnt
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [42] A Randomized Trial of Personalized Cognitive-Behavior Therapy for Alcohol Use Disorder in a Public Health Clinic
    Coates, Jason M.
    Gullo, Matthew J.
    Feeney, Gerald F. X.
    Young, Ross M.
    Connor, Jason P.
    FRONTIERS IN PSYCHIATRY, 2018, 9
  • [43] Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial
    Grodin, Erica N.
    Nieto, Steven J.
    Meredith, Lindsay R.
    Burnette, Elizabeth
    O'Neill, Joseph
    Alger, Jeffry
    London, Edythe D.
    Miotto, Karen
    Evans, Christopher J.
    Irwin, Michael R.
    Ray, Lara A.
    ADDICTION BIOLOGY, 2022, 27 (04)
  • [44] A Commentary on Topiramate Treatment of Alcohol Use Disorder in Veterans with PTSD: A Randomized Controlled Pilot Trial
    Petrakis, Ismene L.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2014, 38 (08) : 2167 - 2168
  • [45] Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial
    Rorsman, I.
    Petersen, C.
    Nilsson, P. C.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (01): : 117 - 124
  • [46] A Randomized Pilot Trial of Brief Family-Involved Treatment for Alcohol Use Disorder: Treatment Engagement and Outcomes
    McCrady, Barbara S.
    Tonigan, J. Scott
    Fink, Brandi C.
    Chavez, Roberta
    Martinez, Amber D.
    Borders, Adrienne
    Fokas, Kathryn
    Epstein, Elizabeth E.
    PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2023, 37 (07) : 853 - 862
  • [47] Neural correlates of drinking reduction during a clinical trial of cognitive behavioral therapy for alcohol use disorder
    Naqvi, Nasir H.
    Srivastava, A. Benjamin
    Sanchez-Pena, Juan
    Lee, Jessica K.
    Drysdale, Andrew T.
    Mariani, John J.
    Ochsner, Kevin N.
    Morgenstern, Jon
    Patel, Gaurav H.
    Levin, Frances R.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 48 (02): : 260 - 272
  • [48] Randomized controlled trial of harm reduction treatment for alcohol (HaRT-A) for people experiencing homelessness and alcohol use disorder
    Collins, Susan E.
    Clifasefi, Seema L.
    Nelson, Lonnie A.
    Stanton, Joey
    Goldstein, Silvi C.
    Taylor, Emily M.
    Hoffmann, Gail
    King, Victor L.
    Hatsukami, Alyssa S.
    Cunningham, Zohar Lev
    Taylor, Ellie
    Mayberry, Nigel
    Malone, Daniel K.
    Jackson, T. Ron
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 67 : 24 - 33
  • [49] RANDOMIZED CONTROLLED TRIAL OF HARM REDUCTION TREATMENT FOR ALCOHOL (HART-A) FOR PEOPLE EXPERIENCING HOMELESSNESS AND ALCOHOL USE DISORDER
    Collins, S. E.
    Clifasefi, S. L.
    Nelson, L. A.
    Stanton, J.
    Goldstein, S. C.
    Taylor, E. M.
    Hoffmann, G.
    King, V. L.
    Hatsukami, A. S.
    Cunningham, Z. L.
    Taylor, E.
    Mayberry, N.
    Malone, D. K.
    Jackson, T. R.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 : 199A - 199A
  • [50] A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial
    Lara A. Ray
    Wave-Ananda Baskerville
    Steven J. Nieto
    Erica Grodin
    Craig Enders
    Annabel Kady
    Lindsay Meredith
    Artha Gillis
    Adam Leventhal
    Diana Ho
    Karen Miotto
    Psychopharmacology, 2024, 241 : 543 - 553